Nevro Corp. (NVRO) News
Filter NVRO News Items
NVRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVRO News Highlights
- For NVRO, its 30 day story count is now at 4.
- Over the past 21 days, the trend for NVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- INGN are the most mentioned tickers in articles about NVRO.
Latest NVRO News From Around the Web
Below are the latest news stories about NEVRO CORP that investors may wish to consider to help them evaluate NVRO as an investment opportunity.
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for NowInvestors continue to be optimistic about Nevro (NVRO) due to its R&D edge. |
Activist investor takes stake in Nevro amid struggles to grow neuromodulation salesEngaged Capital is opposed to Nevro going after acquisitions that may jeopardize its core business, Bloomberg reported Monday. |
Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
What's in Store for Cooper Companies (COO) in Q4 Earnings?Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength. |
Nevro buys low back pain company Vyrsa for $40MThe company expects the acquisition to be revenue accretive starting in 2024. |
Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain TreatmentNevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint. |
Nevro Announces Acquisition of Vyrsa™ TechnologiesNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies ("Vyrsa"), a privately held medical technology company focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI Joint") pain. |
Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should KnowThe mean of analysts' price targets for Nevro (NVRO) points to a 36.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP TreatmentNevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency. |